US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capital Group International Core Equity ETF

28.95

+0.40001.40%

Post-market: 28.950.00000.00%16:04 EDT

Volume:189.72K

Turnover:5.49M

Market Cap:254.88M

PE:- -

High:28.99

Open:28.79

Low:28.78

Close:28.55

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CGIC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGIC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGIC\",,,,,undefined,":{"symbol":"CGIC","market":"US","secType":"STK","nameCN":"Capital Group International Core Equity ETF","latestPrice":28.95,"timestamp":1750795200000,"preClose":28.55,"halted":0,"volume":189717,"hourTrading":{"tag":"盘后","latestPrice":28.95,"preClose":28.95,"latestTime":"16:04 EDT","volume":2,"amount":57.9,"timestamp":1750795448852},"delay":0,"floatShares":8804000,"shares":8804000,"eps":0,"marketStatus":"Not Yet Opened","change":0.4,"latestTime":"06-24 16:00:00 EDT","open":28.79,"high":28.99,"low":28.7792,"amount":5487268.337276,"amplitude":0.007384,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750838400000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":28.55,"sharesOutstanding":9044000,"nav":28.394819,"aum":256802747.22,"dividendRate":0.007599,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.95,"preClose":28.95,"latestTime":"16:04 EDT","volume":2,"amount":57.9,"timestamp":1750795448852},"volumeRatio":1.010808},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGIC\",,,,,undefined,":{"symbol":"CGIC","floatShares":8804000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.010808,"shares":8804000,"dividePrice":0.22,"high":28.99,"amplitude":0.007384,"preClose":28.55,"low":28.7792,"week52Low":23.12,"pbRate":"--","week52High":29.1,"institutionHeld":0,"latestPrice":28.95,"eps":0,"divideRate":0.007599,"volume":189717,"delay":0,"ttmEps":0,"open":28.79,"prevYearClose":24.0456,"prevWeekClose":28.39,"prevMonthClose":28.28,"prevQuarterClose":25.98,"fiveDayClose":28.9,"twentyDayClose":28.125,"sixtyDayClose":26.53},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CGIC\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGIC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524940495","title":"Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524940495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524940495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes  and Clinical Global Impression of Change . Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory. “The presentation of the Extension phase data at AD/PD 2025 is an opportunity to share our findings and engage deeply with the DLB medical community as we plan for pivotal development and work to bring neflamapimod to patients as rapidly as possible,” said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. “The positive findings across the primary outcome measure and multiple additional clinically important endpoints evaluated in the first 16 weeks of the Extension phase strengthen our b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigators-present-clinical-trial-results-110000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO","LU0240877869.USD","LU0345774631.USD","TUG","LU0240878834.USD","LU1169590202.USD","BK4097","DLB","LU0205193047.USD","LU0348723411.USD","CGIC","LU1169589451.USD","PD","BK4023","LU0205194284.USD","LU0345774391.USD","BK4139"],"gpt_icon":0},{"id":"2518889657","title":"CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518889657","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518889657?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":"A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change fro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3040150/0/en/CervoMed-Announces-Positive-Results-from-the-Extension-Phase-of-its-Phase-2b-Clinical-Study-of-Neflamapimod-in-Patients-with-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4528","UK","BK4233","LU0345774631.USD","LU0205193047.USD","BK4207","BK4139","LU0240878834.USD","BK4205","LU0240877869.USD","CRVO","LU0348723411.USD","CGIC","LU1169590202.USD","BK4097","LU0205194284.USD","LU0345774391.USD","DLB","NTB"],"gpt_icon":0},{"id":"2490094676","title":"CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094676","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094676?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—。—Favorable safety and tolerability results with no new safety signal identified—。—Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial—。The full data set from the double-blind phase of the RewinD-LB trial is expected to be available to the Company in January 2025 and the data from the first 16 weeks of the open label extension portion of the trial are expected to be available in the late second quarter of 2025. CervoMed will announce the timing of any presentation of additional data from the RewinD-LB trial at a later date upon completion of the first","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-announces-topline-data-rewind-120000757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0240878834.USD","LU0205194284.USD","LB","LU0348723411.USD","BK4233","CGIC","LU0345774631.USD","DLB","BK4097","BK4213","TUG","LU0205193047.USD","LU0240877869.USD","BK4139","CRVO","LU0345774391.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGIC\",params:#limit:5,,,undefined,":[{"date":"2025-03-31","symbol":"CGIC","amount":0.05758,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Capital Group International Core Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-01"},{"date":"2024-12-26","symbol":"CGIC","amount":0.10356,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-26","defaultRemindTime":1735223400000,"name":"Capital Group International Core Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-26","currency":"USD","dateTimestamp":1735189200000,"payDate":"2024-12-27"},{"date":"2024-09-30","symbol":"CGIC","amount":0.058759,"announcedDate":"2024-09-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-30","defaultRemindTime":1727703000000,"name":"Capital Group International Core Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-01","payableDate":"2024-09-30","currency":"USD","dateTimestamp":1727668800000,"payDate":"2024-10-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGIC\",market:\"US\",,,undefined,":[{"executeDate":"2024-09-30","recordDate":"2024-09-30","paymentDate":"2024-10-01","value":0.058759,"currency":"USD"},{"executeDate":"2024-12-26","recordDate":"2024-12-26","paymentDate":"2024-12-27","value":0.10356,"currency":"USD"},{"executeDate":"2025-03-31","recordDate":"2025-03-31","paymentDate":"2025-04-01","value":0.05758,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGIC\",market:\"US\",delay:false,,,undefined,":{}}}